Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

Projects / Programmes source: ARIS

Preclinical development of a novel inhibitor of class A and class C beta-lactamases

Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B230  Biomedical sciences  Microbiology, bacteriology, virology, mycology 
B510  Biomedical sciences  Infections 
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
Keywords
bacterial resistance, new chemical entities
Evaluation (rules)
source: COBISS
Evaluation of bibliographic research performance indicators according to ARIS methodology
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Researchers (2)
no. Code Name and surname Research area Role Period No. of publications
1.  20246  PhD Andrej Preželj  Biochemistry and molecular biology  Researcher  2005 - 2007  38 
2.  01661  PhD Tomaž Šolmajer  Chemistry  Head  2005 - 2007  380 
Organisations (1)
no. Code Research organisation City Registration number No. of publications
1.  0258  Lek Pharmaceutical Company d.d.  Ljubljana  1732811  8,438 
Abstract
Careful biological evaluation in vitro is key to understand the basis of the antibacterial activity, guiding chemical refinement and assisting subsequent stages providing preliminary indications and evaluations of therapeutic potential.Small-scale screening/initial evaluation of antibacterial potency will be performed (IC50s and Biacore-SPR ranking of all new chemical entities).Clinically relevant pathogens will be employed to establish the antibacterial activity of lead in combination with different (3-lactam antibiotics (In vitro MICs, susceptibility profile).Finally, the project will contribute a vast amount of knowledge to the antimicrobial field. New techniques introduced will represent a screening platform for in-house drug profiling.
Confirmation required
Views history
Favourite